Exporter

EN
FR
Adalimumab
Statut de médicament essentiel
Description générale

INN
Adalimumab
Codes ATC
L04AB04
Type de médicament
Biological agent
Historique des statuts LME
Ajouté pour la première fois en 2019 (TRS 1021) pour Axial spondyloarthritis
Ajouté en 2019 (TRS 1021) pour Rheumatoid arthritis
Ajouté en 2019 (TRS 1021) pour Crohn disease site
Wikipédia
Adalimumab
DrugBank
Adalimumab
Recommandations
Section
Immunomodulators for non-malignant disease
  • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
Indications
Rheumatoid arthritis Axial spondyloarthritis Crohn disease site
Section
Medicines for juvenile joint diseases
  • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
Indications
Juvenile idiopathic arthritis
Section
Dermatological medicines > Medicines affecting skin differentiation and proliferation
  • Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.
Indications
Psoriasis of unspecified type